Cargando…
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
Advances in antibody engineering have led to the generation of more innovative antibody drugs, such as bispecific antibodies (bsAbs). Following the success associated with blinatumomab, bsAbs have attracted enormous interest in the field of cancer immunotherapy. By specifically targeting two differe...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Compuscript
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038071/ https://www.ncbi.nlm.nih.gov/pubmed/36971124 http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0002 |